{"transactions":[{"id":1316,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T22:43:59.000Z","date":"2026-09-01","kind":"purchase","planned":false,"acquired":true,"shares":2098,"price":5.53,"value":11601.94,"ownership":{"direct":true},"balance_after":10708,"source":{"system":"sec-edgar","filing":"0001193125-26-380595","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526380595/ownership.xml","form_type":"4"}},{"id":830944,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:09:55.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120221/ownership.xml","form_type":"4"}},{"id":830943,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:09:55.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":23742,"derivative":{"exercise_price":3.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120221/ownership.xml","form_type":"4"}},{"id":830942,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:09:55.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10362,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0001193125-26-120221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120221/ownership.xml","form_type":"4"}},{"id":830941,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:09:55.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":10362,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":10362,"derivative":{"exercise_price":3.91,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0001193125-26-120221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120221/ownership.xml","form_type":"4"}},{"id":830940,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:09:55.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11463,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":18.24,"expiration_date":"2032-05-04","underlying":"Common Stock","underlying_shares":11463},"source":{"system":"sec-edgar","filing":"0001193125-26-120221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120221/ownership.xml","form_type":"4"}},{"id":830939,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:09:55.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":11463,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":11463,"derivative":{"exercise_price":3.91,"expiration_date":"2032-05-04","underlying":"Common Stock","underlying_shares":11463},"source":{"system":"sec-edgar","filing":"0001193125-26-120221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120221/ownership.xml","form_type":"4"}},{"id":888252,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-23T21:17:18.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date."}],"balance_after":20400,"derivative":{"exercise_price":1.04,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-064028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526064028/ownership.xml","form_type":"4"}},{"id":1042705,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-09-11T22:15:13.000Z","date":"2025-09-09","kind":"grant","planned":false,"acquired":true,"shares":17600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":17600,"derivative":{"exercise_price":3.61,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":17600},"source":{"system":"sec-edgar","filing":"0001411685-25-000076","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000076/edgardoc.xml","form_type":"4"}},{"id":1130697,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T20:17:48.000Z","date":"2025-05-28","kind":"purchase","planned":false,"acquired":true,"shares":8610,"price":1.1769,"value":10133.109,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.17 to $1.18 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."}],"balance_after":8610,"source":{"system":"sec-edgar","filing":"0000950170-25-078982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025078982/ownership.xml","form_type":"4"}},{"id":1135581,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:59:08.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":19111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":19111,"derivative":{"exercise_price":1.19,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":19111},"source":{"system":"sec-edgar","filing":"0000950170-25-077062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025077062/ownership.xml","form_type":"4"}},{"id":1410710,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-10T21:00:07.000Z","date":"2024-09-06","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options (\"Options\") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance (\"Grant Date\"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date."}],"balance_after":14100,"derivative":{"exercise_price":3.25,"expiration_date":"2034-09-06","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001415889-24-023145","document":"form4-09102024_050903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924023145/form4-09102024_050903.xml","form_type":"4"}},{"id":1472250,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T22:18:17.000Z","date":"2024-06-19","kind":"grant","planned":false,"acquired":true,"shares":64503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":64503,"derivative":{"exercise_price":2,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":64503},"source":{"system":"sec-edgar","filing":"0000950170-24-076406","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024076406/ownership.xml","form_type":"4"}},{"id":1591378,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-06T23:00:20.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":12500,"derivative":{"exercise_price":4.85,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-007097","document":"form4-03062024_060311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588924007097/form4-03062024_060311.xml","form_type":"4"}},{"id":1860918,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option\n(right to buy)","published_at":"2023-06-10T00:54:41.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":23742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":23742,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0000899243-23-015320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924323015320/doc4.xml","form_type":"4"}},{"id":2270601,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T01:20:44.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":10362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/12 of the shares shall vest on each monthly anniversary as measured from May 5, 2022."}],"balance_after":10362,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0000899243-22-018286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322018286/doc4.xml","form_type":"4"}},{"id":2278030,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-10T01:39:54.000Z","date":"2022-05-05","kind":"grant","acquired":true,"shares":11463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option shall vest on a monthly basis over a three-year period as measured from May 5, 2022."}],"balance_after":11463,"derivative":{"exercise_price":18.24,"expiration_date":"2032-05-04","underlying":"Common Stock","underlying_shares":11463},"source":{"system":"sec-edgar","filing":"0000899243-22-017371","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322017371/doc4.xml","form_type":"4"}},{"id":2353754,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:13:06.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, which vest in twelve equal monthly installments, beginning on the date of the grant."}],"balance_after":100000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-22-002291","document":"form4-03032022_010341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588922002291/form4-03032022_010341.xml","form_type":"4"}},{"id":2627079,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":1086,"kind":"person","name":"FitzPatrick Margaret M","position":1,"cik":"0001873879","reported_name":"FitzPatrick Margaret M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-22T20:11:26.000Z","date":"2021-07-21","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in twelve equal monthly installments, beginning on the date of the grant. The stock options were granted in connection with the Reporting Person's appointment to the Issuer's Board of Directors and pursuant to the Issuer's 2019 Omnibus Equity Incentive Plan."}],"balance_after":75000,"derivative":{"exercise_price":2.93,"expiration_date":"2031-07-21","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001415889-21-003674","document":"form4-07222021_010706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000141588921003674/form4-07222021_010706.xml","form_type":"4"}}]}